Rubedo Life Sciences, a biopharmaceutical company dedicated to developing advanced therapies targeting senescent cells linked to age-related diseases, has announced the opening of its European headquarters and clinical operations in Milan. This expansion precedes the company’s inaugural in-human Phase 1 study for RLS-1496, a leading treatment for inflammatory skin conditions, set to begin in Europe early next year. This marks Rubedo’s first clinical trial and operations outside its California headquarters, highlighting the global significance of age-related diseases.
“As we transition to a clinical-stage company, we have an excellent opportunity to harness world-class talent and infrastructure in Europe to turn our pioneering research on cellular senescence into top-tier therapies for patients with skin conditions and aging skin,” said Marco Quarta, CEO & Co-Founder of Rubedo Life Sciences. “With backing from prominent EU investors like CDP Venture Capital, we are thrilled to expand into Europe, truly becoming an international company.”
“We are excited to support Rubedo Life Sciences’ growth in Italy, aligning with the country’s priorities of boosting investments in AI and biotech while attracting top talent. This investment underscores our commitment to innovation and reinforces Italy’s status as a hub for these impactful sectors,” added Agostino Scornajenchi, CEO and Managing Director of CDP Venture Capital.
RLS-1496 is a topical therapeutic agent, with the Phase 1 study focusing on patient safety as its primary endpoint. Secondary endpoints will evaluate cellular senescence and related disease biomarkers. The treatment was designed as a topical solution to provide a more effective proof of concept than systemic therapies.
About Rubedo Life Sciences
Rubedo Life Sciences is a biopharmaceutical company dedicated to developing innovative therapies that target cells involved in chronic age-related diseases. Utilizing our proprietary ALEMBIC™ drug discovery platform, we have created novel small molecules that selectively address various types of senescent cells, which contribute to the progression of disorders such as lung, skin, oncologic, neurodegenerative, and fibrotic diseases. Our leadership team consists of experts from the chemical, engineering, and life sciences fields, with extensive experience in drug development and commercialization from both large pharmaceutical and leading biotech companies. The company is headquartered in Sunnyvale, CA, USA.
